Navigation Links
Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75

Phase III Clinical Data on Thalidomide in Multiple Myeloma Presented at the American Society of Clinical Oncology 43rd Annual Meeting

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation today reported the final results of a Phase III study demonstrating that the addition of Thalidomide to standard therapy improves overall survival (OS) by 17.6 months in patients aged 75 or older with newly diagnosed multiple myeloma compared to the current standard of care. These results were reported in an oral presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. (June 1-5, 2007). An additional two oral and six poster sessions on Thalidomide were also presented at the conference.

"These latest data on Thalidomide treatment in patients over the age of 75 are consistent with previous studies demonstrating Thalidomide's benefit in a first-line treatment setting," said Patrick J. Mahaffy, Pharmion's president and CEO. "We believe these data provide additional validation to those data already on file with the EMEA for Thalidomide in the treatment of newly-diagnosed myeloma, and also support its use in patients aged 75 years or older with myeloma, which represent more than 20 percent of the myeloma patient population."

The Phase III dual-arm randomized study compared overall survival in patients receiving standard therapy of melphalan and prednisone plus placebo (MP-placebo) or standard therapy plus Thalidomide (MP-T). A total of 232 patients were randomized to one of the two treatment arms and the results from 200 patients were available for presentation. In the final analysis, the median overall survival in the MP-T arm was 45.3 months, compared to 27.7 months for the MP-placebo (p=0.05 log-rank test).

Thalidomide was well tolerated by the majority of patients, but, in combination with other treatments, was associated with a higher incid
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
2. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
3. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
4. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
5. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
6. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
7. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
8. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
9. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
10. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
11. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
Post Your Comments:
(Date:5/22/2008)...didate, RDEA806, Demonstrated No Reproductive Toxi... -, - RDEA427 Selected as Clinical Candidate, Demo...ential for Once Daily Oral Dosing -, SAN DIEGO, M... Inc.,(Nasdaq: RDEA ) today announced preclinical...tase inhibitor (NNRTI) candidate, RDEA806, demonst...
(Date:5/21/2008)...derscore the Utility of CAPHOSOL in Treating Oral ...- New data show that CAPHOSOL(R), (http://www.caph...eves painful oral,mucositis (OM) and improves qual...erapy and radiation therapy. These data were repor... 33rd Annual Congress of the,Oncology Nursing Soci...
(Date:5/21/2008)...nted at 12th World Congress on the Menopause show ...yspareunia, two of the most frequent s... ARBOR, Mich., May 21 /- QuatRx Pharm...rom a pivotal Phase 3 study of Ophena(TM),(ospemif...mptoms of,vulvovaginal atrophy, a common condition...
(Date:5/21/2008)...EIGHTS, N.J., May 21 /- Gen...ed that multiple abstracts,featuring its lead onco...meeting of the American Society of Clinical Oncolo...he abstracts include the following:, -- Initial ... G4544, an oral gallium-containing Compound. ...
Breaking Medicine Technology:Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 2Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 3Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 4CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 2CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 3CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 4CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 5CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 6QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy 2QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy 3Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology 2Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology 3FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 1FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 2FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 3FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 4FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 5QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena 28TM 29 28ospemifene 29 to Treat Postmenopausal Vaginal Syndrome 1131 1QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena 28TM 29 28ospemifene 29 to Treat Postmenopausal Vaginal Syndrome 1131 2QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena 28TM 29 28ospemifene 29 to Treat Postmenopausal Vaginal Syndrome 1131 3Hookah Smoking as Tough on Lungs as Cigarettes 9019 1Hookah Smoking as Tough on Lungs as Cigarettes 9019 2Hookah Smoking as Tough on Lungs as Cigarettes 9019 3Novel anticancer strategy moves from laboratory to clinic 9014 1Novel anticancer strategy moves from laboratory to clinic 9014 2Novel anticancer strategy moves from laboratory to clinic 9014 3
...in Key Lung Compartments, REINACH and BASEL, Switz...rpida Ltd. today announced promising,results of "f...led,Human Microdose studies included a total of 19...udy is the first ever using Microdosing,for the de...ments.,The results showed that AR-709 achieves hig...
...Mar 29, 2007 - ACADIA Pharmaceuticals,Inc. (Nasdaq...ovative technology to fuel drug discovery and clin...ervous system,disorders, today announced that the ...gress on Schizophrenia Research, held from,March 2...rado.,Presentations will cover ACADIA,s two schizo...
Other Medicine Technology:Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 2ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 3ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 5
(Date:5/22/2008)... in progression of risk factors as subjects aged ,...New insights into lung disease and lung function i..., The researchers analyzed data from the U.S. Nat...oronary Artery Risk Development in Young Adults) o...ears of health assessments in more than 5,000 youn...
(Date:5/22/2008)...illion Americans whove received drug-eluting stent...right future, according to new research from the U...The findings, among the first large follow-up stud...uting stents compared to bare metal stents, will b...the American College of Cardiology. Patients with ...
(Date:5/22/2008)...ozed at wheel; National Road Safety Fou...W YORK, May 22 /PRNewswire/ -- As people jam the r...hich marks the start of the peak summer,driving se...into -- a,drowsy driver, says the National Road Sa...vides free driver safety films and programs includ...
(Date:5/22/2008)...ewswire/ -- Many baby boomers,incorrectly believe ...to a,new survey conducted by Harris Interactive(R)...IP). Most say that disability insurance is importa...ey do not have any disability,income protection., ...830/AHIPLOGO ), "Baby boomers recognize the valu...
Breaking Medicine News(10 mins):Health News:CARDIA Studies Open Window on Heart, Lung Diseases 2Health News:CARDIA Studies Open Window on Heart, Lung Diseases 3Health News:More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures 2Health News:Drowsy Driving as Dangerous as Drunk Driving 2Health News:Many Baby Boomers Incorrectly Believe They Are Protected Against the Risk of Disability 2Health News:Many Baby Boomers Incorrectly Believe They Are Protected Against the Risk of Disability 3
... labeling has been introduced in Canada for most p...ontribute towards the good health of Canadians in ... from partial hydrogenation, which is an industria...le oils and extends their shelf life in addition t...
... U.S. Congress called on Monday for more rigorous ...nts.// The Food and Drug Administration (FDA) has...ng -- but significant gaps remain, according to Re... Democrat on the House Appropriations subcommittee...
...deal with a nearly certain outbreak of a bird flu ...ys a top EU medical expert.// Professor Johan Gi...on and Control (ECDC) was speaking after chief vet...25 EU nations met to discuss protecting European w...
... scientists has sparked new fears over the safety ...hey should eat no more than two portions a year.//... New York State University, concluded that the hea...tish fish are outweighed by risks caused by pollut...
Other Medicine News:Health News:Scrutiny Sought For Reused Devices in U.S. 2Health News:EU medical chief says Europe ready for bird flu 2Health News:Salmon's own diet sure to affect yours 2
Volk's super series slit lamp biomicroscopy lenses. General retinal scanning situations. Provide unprecedented fundus diagnostic capability, specifically addressing maximum potential field of view, f
Volk indirect lenses. High magnification views of the posterior pole.
Precision has its new line of programmable autoclaves which are easy to use bench-top autoclaves or models to fit any need. It has 4 adjustable sterilization programs, touch button control panel, man
...ina Tomograph is a confocal laser scanning microsc...nal images of the posterior segment. It enables th...y and precise follow-up of topographic changes. Th...eidelberg Retina Tomograph is the topographic desc...
Medicine Products: